Hemp law in America just went through its biggest shift since the 2018 Farm Bill, and most people buying products off a smoke-shop shelf have no idea it happened. This post walks through where federal and state law actually stand right now, and where religious-use arguments fit into that picture — including the framework that's shaping the next round of RFRA and RLUIPA litigation.

(Not legal advice — this is a plain-language map of the law as it stands and the arguments being made around it. Talk to an attorney about your specific situation.)

Buried inside H.R. 5371 — the appropriations package that ended the government shutdown — was Section 781, which rewrites the federal definition of hemp for the first time since 2018. It was signed into law on November 12, 2025, with a one-year runway before enforcement: the new rules take effect November 12, 2026.

Two changes matter most:

• "Total THC" replaces Delta-9-only testing. The 2018 Farm Bill's 0.3% threshold was measured on Delta-9 THC alone. The new law counts Delta-9 plus THCA (its non-intoxicating precursor) toward that 0.3% limit. Because raw cannabis naturally carries much more THCA than Delta-9, a lot of plant material that was "compliant hemp" under the old math will not be under the new math.
• A 0.4 milligram per-container cap on finished products. Not 0.4%, not 0.4mg per serving — 0.4mg of Total THC in the entire container. For scale, a typical Delta-8 gummy today runs 10–25mg, and THCA flower runs into the hundreds of milligrams. Industry estimates put the share of currently-sold hemp products that will fail to meet this bar above 90%.

Plus: synthetic and chemically-converted cannabinoids (most Delta-8 as it's actually made) are excluded from the hemp definition outright.

What this doesn't touch: buying, possessing, and consuming compliant hemp products remains fully legal federally — that's settled since 2018. What's changing is which products qualify as compliant, and it guts the market for anything intoxicating. Industrial hemp (fiber, grain, building material) isn't affected at all.

What's still true, and often missed: the USDA hemp program has never authorized casual home cultivation for personal use, license or no license. Growing hemp — even fully compliant, sub-0.3% hemp — has always required a commercial registration, a state or USDA cultivation plan, and pre-harvest testing. That was true before this law and remains true after it. It's a separate question from what you can buy at a store.

Long before H.R. 5371, the Hemp Industries Association (HIA) fought and won the case that first drew the natural-vs-synthetic line the new law now leans on. In Hemp Industries Association v. DEA (9th Cir. 2004), HIA — representing companies importing and selling sterilized hemp seed, seed oil, and seed cake — challenged DEA rules that would have banned those products for containing trace, non-psychoactive THC. The Ninth Circuit sided with HIA: the "THC" entry in Schedule I refers only to synthetic THC. Naturally-occurring THC inside the cannabis plant is governed separately by the Schedule I "marihuana" definition, not the THC entry — so a product made from hemp seed, containing only trace natural THC and no THC synthesized in a lab, was never within DEA's authority to ban under that regulation. That ruling is why the hemp seed and seed-oil trade has been legally insulated for two decades.

Seeds under H.R. 5371. The new law writes a version of that same natural/synthetic-adjacent logic directly into the statute, but narrows it. Under the amended definition (7 U.S.C. § 1639o), "hemp" includes the seeds of the plant — but viable seeds are explicitly excluded from the hemp definition if the parent plant exceeds 0.3% Total THC. In practice: seed derived from a compliant, sub-threshold hemp plant is still hemp; seed from a plant that tested over the Total THC line — even if the seed itself carries no meaningful THC — is not, and falls back into the marijuana definition. Seeds intended for planting toward industrial uses (fiber, grain, seed oil, microgreens) are carved out as "industrial hemp" and get somewhat more protection from the intoxicating-product restrictions than consumable cannabinoid products do.

Synthetic and converted cannabinoids. This is where H.R. 5371 goes further than the 2004 case ever addressed. The law excludes from the hemp definition any cannabinoid that is either (1) not capable of being naturally produced by a Cannabis sativa L. plant at all, or (2) capable of being naturally produced by the plant, but was actually synthesized or chemically converted outside the plant. That second category is the one that matters most commercially — it's exactly how nearly all Delta-8 THC on the market is made: not extracted from the plant in meaningful quantities, but produced by acid-catalyzed conversion from hemp-derived CBD in a lab. Under the 2004 HIA precedent, that kind of THC would likely have been treated as the "synthetic" THC DEA was always allowed to schedule. H.R. 5371 makes that explicit and comprehensive: it doesn't matter that the cannabinoid also occurs naturally in the plant — if it was made outside the plant, it's excluded from hemp regardless of concentration, full stop.

Put together, the throughline is this: the same synthetic/natural distinction HIA established in court to protect trace-THC seed and fiber products from an overreaching DEA rule is now the exact fault line Congress used to exclude the intoxicating hemp-derived market (mostly built on converted Delta-8 and similar cannabinoids) from the legal definition of hemp altogether.

The unresolved conflict: can a "Total THC" number, by itself, make something illegal? Here's where H.R. 5371 runs into a structural problem HIA already litigated. Schedule I of the CSA lists two separate things: "marihuana" (defined by reference to specific parts of the plant — the leaves, flowering tops, resin — while expressly excluding mature stalk, fiber, sterilized seed, and oil or cake made from the seed) and, separately, "tetrahydrocannabinols." HIA's holding was that the second entry, "THC," has only ever covered synthetic THC — natural THC inside the cannabis plant is reachable only through the marihuana definition, and only if the material in question actually falls within marihuana's specific list of covered plant parts. The court was explicit that Congress passed the THC and marihuana provisions without repealing or merging either one, so DEA doesn't get to use the THC listing as a backdoor to control natural plant material that the marihuana definition itself exempts.

H.R. 5371's core compliance test — 0.4 milligrams of Total THC per container — is a pure THC-content measurement. It doesn't ask whether the product falls within marihuana's specific list of plant parts; it asks how many milligrams of naturally-occurring THC (Delta-9 plus THCA) are present, full stop. Under HIA's reading of Schedule I, a milligram count of natural THC isn't, by itself, the "THC" Schedule I entry — that entry doesn't reach natural THC at all. So a hemp-derived product that fails the 0.4mg container cap doesn't automatically become illegal "THC" under the entry HIA construed; for it to be a controlled substance, it would separately have to qualify as "marihuana" or a "marihuana extract" under that definition's own terms — a different, plant-parts-based test that a finished beverage, gummy, or isolate-based product doesn't obviously satisfy just because a lab found more than 0.4mg of natural THC in it.

The likely government response is that this misreads what H.R. 5371 actually amends: the bill doesn't touch the Schedule I "tetrahydrocannabinols" entry at all — it rewrites the hemp definition in the Agricultural Marketing Act, which is cross-referenced directly into the CSA's "marihuana" exclusion (21 U.S.C. § 802(16)). On that reading, anything that fails the new hemp definition — including on the container-cap test — simply falls back into "marihuana" by definition, without ever needing the separate "THC" entry to do any work, and HIA's synthetic-only holding about that entry becomes beside the point. Whether a container-based Total THC number can validly redefine "marihuana" itself in a way that reaches products outside marihuana's traditional plant-parts list — beverages, isolates, converted extracts — is exactly the kind of question that hasn't been tested in court yet, and it's a live opening for exactly the kind of APA/statutory-construction challenge HIA itself was built on.

A lot of confusion in this space comes from conflating three different layers of law:

1. Federal retail legality — governed by the Farm Bill / H.R. 5371 math above.
2. State restrictions — states are free to ban or restrict products (Delta-8, THCA flower) that are federally legal hemp. Texas has done exactly this: a broad smokable-hemp ban and a Texas Supreme Court move reclassifying non-Delta-9 isomers as Schedule I.
3. Local/municipal enforcement policy — cities can't rewrite drug law, but they can direct their own police not to prioritize it. Dallas's Proposition R (the Dallas Freedom Act) directs local police not to cite or arrest for possession up to 4 ounces, and bars using the smell or sight of cannabis as probable cause on its own. Texas's Attorney General sued to block it, and the fight over whether cities can do this is ongoing — Austin's own decriminalization ordinance was struck down by the Texas 15th Court of Appeals in April 2025 after a similar AG challenge.

The "smokable" carve-out is a narrower fix than it looks. Texas's ban targets a delivery method — smokable flower — rather than THC content itself, and critics of that approach point out the obvious gap: banning one form of consumption doesn't reduce demand for the cannabinoid, it just redirects it. Consumers who can't buy smokable flower don't uniformly switch to sodas and non-intoxicating products; some do, but others shift to gummies, vapes, or other ingestible forms that deliver the same THC without triggering the smokable-specific rule, and some simply move to the unregulated illicit market instead. A regulatory line drawn around form rather than content is inherently porous in that way — it's a real tension in how Texas has chosen to write these bans, separate from the federal Total-THC/container approach discussed above.

Texas's political fight, in short: Governor Abbott vetoed Senate Bill 3 in June 2025 — the bill that would have banned all consumable hemp with any THC — citing constitutional defects and federal preemption problems, and pointing to Arkansas's similar ban being tied up in litigation for years. His preferred approach is regulation (age-gating at 21, potency limits, banning synthetics) rather than prohibition, putting him at odds with Lt. Gov. Dan Patrick, who has pushed a full ban as a longstanding priority. Abbott has since used an executive order (GA-56) to direct DSHS and TABC toward age-verification and licensing enforcement rather than a blanket ban. The federal 0.4mg cap now arriving in 2026 is, in practice, stricter than what Abbott himself proposed.

Who supplies the shelf: compliant hemp travels a normal B2B freight chain — licensed farms sell raw biomass to extraction labs, labs convert it to distillate/isolate backed by a Certificate of Analysis, brands and multi-state operators package it, and wholesale distributors sell it into local stores. It's ordinary interstate commerce because hemp was removed from the Controlled Substances Act in 2018 — which is exactly the protection Section 781 narrows.

This is the part most coverage skips, and it's the part that's about to matter more, not less, as the recreational hemp market shrinks.

The legal tools. There's no line in the Controlled Substances Act or the Farm Bill carving out cannabis for religious use, the way the Volstead Act carved out sacramental wine during Prohibition. The pathway instead runs through the Religious Freedom Restoration Act (RFRA) federally, and RLUIPA and state-level "mini-RFRAs" (Texas has its own, TRFRA) at the state level. Under RFRA, if a law substantially burdens sincere religious exercise, the burden is on the government — not the petitioner — to prove the restriction is the least restrictive means of serving a compelling interest. DEA's own petition guidance opens with this exact standard: once a petitioner shows (1) sincere (2) religious exercise (3) substantially burdened by the CSA, DEA has to justify a denial by meeting that test — it doesn't get to simply decline.

The GAO has already told Congress DEA is failing at this. In May 2024, the Government Accountability Office published GAO-24-106630, "DEA Should Improve its Religious Exemptions Petition Process for Psilocybin (Mushrooms) and Other Controlled Substances." The numbers GAO pulled directly from DEA are stark: over the eight-year period from fiscal year 2016 through January 2024, 24 petitioners requested a religious exemption from the CSA for various controlled substances. Not one had been granted. Of six psilocybin petitions specifically, three were withdrawn and three were still pending — those pending ones had already been sitting for 8 months to over 3 years. GAO also found petitions for other controlled substances that had been pending for almost five years and almost eight years with no final determination. The report's central finding was that DEA's own guidance sets no timeframe for deciding a petition at all — petitioners have no way to know whether a decision is coming in months or years. DEA formally concurred with all of GAO's recommendations to fix this.

What's happened since underscores the point. Every actual grant since GAO's report has come either through a settled lawsuit (the Church of the Eagle and the Condor, 2024) or, in one case in 2025, a petition DEA finally approved administratively (Church of Gaia, for ayahuasca) — the first time that's happened without litigation forcing it. That's the pattern GAO documented from the government's own data: an agency that, left to its own process with no deadline, effectively defaults to years of silence rather than the reasoned grant-or-deny determination its own guidance says it will issue. That's the institutional backdrop against which any new religious cannabis petition would be filed — not a hypothetical bureaucratic risk, but a documented, GAO-confirmed pattern.

It's a two-track petition process — SBREFA-style, in spirit. A grant of religious exemption from the CSA itself doesn't automatically clear every regulatory hurdle. A petitioner remains bound by DEA's registration, quota, recordkeeping/reporting, security, and inspection rules unless they separately petition for exemption from those specific regulations under 21 C.F.R. § 1307.03 — addressing each one individually and stating the reasons for seeking exemption from it. It's the same basic idea behind SBREFA-type regulatory-flexibility petitions elsewhere in federal law: the underlying prohibition and the compliance machinery built around it are two different things, and you can seek relief from the machinery — quotas, paperwork, reporting — separately from the exemption itself. One petition gets you past the CSA's blanket prohibition; the second, regulation-by-regulation petition is what gets you out from under the requirements that would otherwise still apply.

Real precedent exists. The Supreme Court's Gonzales v. O Centro Espírita Beneficente União do Vegetal (2006) held the government couldn't bar a church's ayahuasca (DMT) use without meeting that strict-scrutiny bar — and the DEA has granted RFRA-based exemptions to the UDV and Santo Daime churches by court order. The Ninth Circuit's Oklevueha Native American Church v. Holder (2012) confirmed a plaintiff doesn't have to exhaust a DEA administrative petition before bringing a RFRA claim in federal court. Peyote use by the Native American Church has an explicit statutory exemption (in federal law and in Texas's own controlled substances code). None of that guarantees a cannabis outcome, but it establishes that courts will order exemptions for sincere sacramental drug use when the government can't clear strict scrutiny — cannabis is not automatically different in kind.

What counts as a "religion" for this purpose. Africa v. Commonwealth (3d Cir.) set the test courts still lean on: beliefs have to address "ultimate" questions, form a comprehensive theology rather than a single issue, and show the structural markers of a religion — organization, practice, continuity. It's why Church of Reality-type claims built around health benefits rather than theology have failed, and why a group built around a genuinely comprehensive belief system, sustained practice, and an organized body has a stronger foothold than a one-off possession defense.

Texas doesn't write cannabis into its statute, but it doesn't have to. Texas Health & Safety Code § 481.002 names peyote explicitly for the Native American Church and stops there — there's no mirroring line for cannabis. Advocates working this angle point to two structural features instead: the statute's own "unless the context otherwise requires" language at the top of its definitions section, and the fact that Texas already carves out non-commercial handling for research, lab analysis, and law enforcement purposes without requiring a commercial license. The argument is that if the state already treats non-recreational, non-commercial possession differently in those lanes, a sincere religious/sacramental use sits in the same structural category — not that the statute names it, but that the statute's own logic doesn't reach it. That's a real argument being made; it hasn't been tested to a final ruling in Texas courts, and TRFRA claims still have to clear strict scrutiny case by case.

Texas has real case history here. Beyond the peyote exemption, Texas has seen religious-freedom challenges to marijuana enforcement litigated in federal court — for example Gallagher v. Austin Police Department (W.D. Tex., No. 1:16-CV-527-RP, before Judge Robert Pitman), part of a broader wave of civil-rights challenges to local marijuana enforcement that ran alongside Austin's own decriminalization push (the city council's 2020 resolution, APD's 2020 policy change, and the 2022 voter-approved measure that was later struck down on appeal).

Why the timing argument matters. Up to now, a religious-necessity claim for cannabis has run into an awkward rebuttal: if hemp-derived THC is legal to buy recreationally anyway, why does anyone need a religious exemption? That undercuts the "substantial burden" argument RFRA requires. Once the 0.4mg cap actually takes effect on December 31, 2026 (after the one-year grace period), that rebuttal mostly disappears — recreational access to anything above trace amounts goes away, while medical and religious pathways remain the only routes to meaningful access. That's a real structural shift in how these cases will be argued going forward, not a guarantee of any particular outcome.

Section 781's "Total THC" shift changes the compliance math, but it doesn't touch a separate legal question that's been building for a few years: whether newer cannabinoids are even legally the same thing as THC.

The Federal Analogue Act (21 U.S.C. § 813) only reaches substances "substantially similar" in chemical structure and pharmacological effect to a scheduled drug, with intent for human consumption. That's a narrower bar than "related to" — tryptophan isn't banned despite structural kinship to Schedule I tryptamines, because the specific structural differences matter to the legal test, not just family resemblance.

• THCp (tetrahydrocannabiphorol) has a 7-carbon side chain versus Delta-9's 5-carbon chain, was only identified in 2019, and binds cannabinoid receptors far more potently — differences advocates argue take it outside "substantially similar."
• THCJD (tetrahydrocannabioctyl) goes further, with an 8-carbon chain, a different binding profile, and identification going back to the early 1940s — predating modern scheduling entirely, which cuts against treating it as a designer analogue built to dodge the law.

Whether these hold up as "not substantially similar" to THC is untested and will likely get litigated directly. And it's a separate track from the religious-exemption argument above — even a cannabinoid found to be a straightforward THC analogue is still eligible for RFRA/RLUIPA protection in a sincere religious-use case; the two arguments aren't mutually exclusive.

Federal hemp law just narrowed sharply, state and local rules remain a patchwork on top of it, and the loophole religious-exemption advocates have always faced — "you can just buy this legally anyway" — is closing. That doesn't settle any individual case, but it changes the shape of the argument going into 2027. Real Supreme Court and appellate precedent (O Centro, Oklevueha, the peyote exemption, Africa v. Commonwealth) shows courts will order religious exemptions for sacramental substance use when the government can't clear strict scrutiny. Whether that extends to cannabis, and on what facts, is the fight that's about to get a lot more live.